Aadi Bioscience (NASDAQ:AADI – Get Free Report) and Oncobiologics (NASDAQ:OTLK – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, risk, analyst recommendations, valuation, institutional ownership and profitability.
Profitability
This table compares Aadi Bioscience and Oncobiologics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Aadi Bioscience | -246.06% | -71.87% | -57.28% |
| Oncobiologics | N/A | N/A | -254.82% |
Analyst Recommendations
This is a summary of recent ratings and target prices for Aadi Bioscience and Oncobiologics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Aadi Bioscience | 0 | 0 | 0 | 0 | 0.00 |
| Oncobiologics | 1 | 4 | 2 | 0 | 2.14 |
Risk and Volatility
Aadi Bioscience has a beta of 0.68, meaning that its stock price is 32% less volatile than the S&P 500. Comparatively, Oncobiologics has a beta of 0.82, meaning that its stock price is 18% less volatile than the S&P 500.
Valuation & Earnings
This table compares Aadi Bioscience and Oncobiologics”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Aadi Bioscience | $25.07 million | 4.76 | -$65.76 million | ($2.35) | -2.06 |
| Oncobiologics | $1.35 million | 71.24 | -$62.42 million | ($0.77) | -0.84 |
Oncobiologics has lower revenue, but higher earnings than Aadi Bioscience. Aadi Bioscience is trading at a lower price-to-earnings ratio than Oncobiologics, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
52.1% of Aadi Bioscience shares are owned by institutional investors. Comparatively, 11.2% of Oncobiologics shares are owned by institutional investors. 37.3% of Aadi Bioscience shares are owned by company insiders. Comparatively, 1.8% of Oncobiologics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Summary
Oncobiologics beats Aadi Bioscience on 10 of the 14 factors compared between the two stocks.
About Aadi Bioscience
Aadi Bioscience, Inc., a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa. The company is also involved in evaluating FYARRO in cancers, including indications targeting specific genomic alterations that activate the mTOR pathway. Aadi Bioscience, Inc. was incorporated in 2007 and is headquartered in Pacific Palisades, California.
About Oncobiologics
Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.
Receive News & Ratings for Aadi Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aadi Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
